Novel Treatment for the hardest-to-treat Schizophrenia: Dual Activation of NMDA Receptor and Antioxidant

ASIA unversity > 醫學暨健康學院 > 心理學系 > 期刊論文 > Item 310904400/112768

jsp.display-item.identifier=請使用永久網址來引用或連結此文件: http://asiair.asia.edu.tw/ir/handle/310904400/112768

题名:	Novel Treatment for the hardest-to-treat Schizophrenia: Dual Activation of NMDA Receptor and Antioxidant
作者:	Chieh-Hsin, L;Lin, Chieh-Hsin;Chen, Yu-Ming;Chen, Yu-Ming;藍先元;Lane, Hsien Yuan
贡献者:	心理學系
日期:	2019-10
上传时间:	2020-08-27 08:08:33 (UTC+0)
出版者:	亞洲大學
摘要:	Clozapine has been regarded as the last-line antipsychotic agent for patients with refractory schizophrenia. However, many patients remain unresponsive to clozapine, referred to as “clozapine-resistant”, “ultra-treatment-resistant”, or “hardest-to-treat”. There has been no convincing evidence for augmentation on clozapine so far. Novel treatments including numerous N-methyl-D-aspartate (NMDA) receptor (NMDAR) enhancers such as glycine, D-serine, D-cycloserine, and N-methylglycine (sarcosine) failed in clinical trials. Earlier, Inhibition of D-amino acid oxidase (DAAO) that may metabolize D-amino acids and thereby activate NMDAR has been reported to be beneficial for patients with schizophrenia receiving antipsychotics except clozapine. A recent randomized, double-blind, placebo-controlled clinical trial found that add-on sodium benzoate, a DAAO inhibitor, improved the clinical symptoms in patients with clozapine-resistant schizophrenia, possibly through DAAO inhibition (and thereby NMDAR activation) and antioxidation as well; additionally, sodium benzoate showed no obvious side effects, indicating the treatment is safe at the doses up to 2 g per day for 6 weeks. More studies are warranted to elucidate the mechanisms of sodium benzoate for the treatment of schizophrenia and thereby the etiology of this severe brain disease. If the finding can be reconfirmed, this approach may bring new hope for the treatment of the most refractory schizophrenia. This review summarizes current status of clinical trials and related mechanisms for treatment-resistant, especially, clozapine-resistant schizophrenia. We will also highlight the importance of understanding the molecular circuit switches that can restore brain function in patients with schizophrenia and discuss future directions in developing better treatments for the hardest-to-treat schizophrenia.
關聯:	CURRENT DRUG TARGETS
显示于类别:	[心理學系] 期刊論文

文件中的档案:

档案	描述	大小	格式	浏览次数
index.html		0Kb	HTML	236	检视/开启

检视Licence

在ASIAIR中所有的数据项都受到原著作权保护.

数据加载中.....